Daesung Microbiological Laboratories Co., Ltd.
KKRX:0364805,640.00
KRW
+40.00
(+0.71%)
ISIN
KR7036480002
Return %
Stock
S&P 500
1Y
-24.30
14.39
3Y
-61.18
81.42
5Y
-64.75
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 138
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Uiwang-si South Korea
- IPO Date
- Apr 4, 2000
- Website
- dsmbio.com
- Similar Companies
- Business
- Daesung Microbiological Laboratories Co., Ltd. is a South Korea-based veterinary pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and distribution of animal medicines, biological products, and healthcare formulations for livestock and companion animals. Founded in 1968 and headquartered in Uiwang-si, Gyeonggi-do, South Korea, the company operates across the animal health, agricultural biotechnology, and veterinary pharmaceuticals sectors, serving livestock farms, veterinary clinics and hospitals, feed manufacturers, and international distribution partners. The company offers a comprehensive range of veterinary products organized by therapeutic category and target species, including swine, cattle, poultry, companion animals, and aquatic species. Its core product portfolio comprises veterinary biologicals and vaccines, such as Foot-and-Mouth Disease (FMD) vaccines, swine erysipelas vaccines (Danyeol PigVac), porcine circovirus vaccines (DS CIRCO PigVac), porcine reproductive and respiratory syndrome vaccines (DS PRRS ChimeVac), avian influenza vaccines, Newcastle disease vaccines, and companion animal virus-like particle formulations including VLP FLU; antibiotics, antibacterials, and anti-inflammatory injectables, such as sustained-release penicillin-streptomycin treatments (PPS Long-Acting Injection), amoxicillin preparations, and enrofloxacin formulations; anthelmintics and parasiticides, including Anthelmin tablets and broad-spectrum internal and external parasite controls; biosecurity disinfectants and environmental sanitation agents, including DS HIGH-CLEAN; digestive enzymes, probiotics, and microbial feed additives, such as DS CLEANER POWDER and DS Avilac; nutritional therapeutics and metabolic stimulants, including iron injections for anemia prevention (DS FERRUM 200 Inj.), multi-vitamin and amino acid complexes (DS COMBICOM-C Inj. and DS AMIVICOM Inj.), and electrolyte supplements; as well as reproductive hormones and bovine mastitis ointments. In recent major developments, Daesung Microbiological Laboratories underwent a change in controlling ownership and corporate restructuring following the acquisition of management control by Insilico Co., Ltd., an artificial intelligence-driven data analytics and molecular modeling firm. Under the leadership of Chief Executive Officer Seung-Hoon Choi, the company has implemented a major strategic shift to integrate AI technologies and digital transformation platforms into its veterinary drug discovery, vaccine design, and Good Manufacturing Practice (GMP) production processes to enhance R&D efficiency. Concurrently, the company adopted a corporate value enhancement roadmap targeting expanded commercialization across global bio-markets, broadened its companion animal healthcare portfolio through the showcase of advanced vaccines including VLP FLU, and expanded its international export activities across Asia and emerging veterinary markets.